Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Academic Drug Discovery

Gemma Nixon's Biography

Gemma Nixon, Lecturer, University of Liverpool

Dr Gemma Nixon's research career began with the completion of a PhD for Dr Ian O’Neil (University of Liverpool) in 2006. She then completed a one year Post Doctoral position with Prof Paul O’Neill (University of Liverpool) working on endoperoxide antimalarials (AntiMal) before joining the company Peakdale Molecular in Januray 2008. In March 2009 she began a Post Doctoral position at Liverpool School of Tropical Medicine (LSTM) with Prof Steve Ward working on a Seeding Drug Discovery Malaria Project before moving to a Scientific Team Leader role with Prof Giancarlo Biagini on an MRC DFPS funded TB Drug Development Program. In 2013 Gemma took up the role of Chemistry Team Leader on the AWOL II: Macrofilaricidial Drug Discovery Project at LSTM whilst pursuing her own independent research interests.
In April 2015 Gemma was appointed to a joint lectureship in Medicinal Chemistry between the Department of Chemistry and the Institute of Translational Medicine at the University of Liverpool. In May 2016 Gemma was awarded an MRC New Investigator Research Grant to investigate the 'Rational Design, Synthesis and Biological Evaluation of Benzimidazoles; Towards a Novel Therapy Selectively Targeting C. neoformans ß-tubulin'. Research interests include several areas of medicinal chemistry drug discovery and target identification. With a strong emphasis on development of novel therapies used in the treatment of tuberculosis, malaria, Cryptococcus neoformans and filariasis.

Gemma Nixon Image

The Discovery and Development of E209 - a Tetraoxane Based Rapidly Acting Antimalarial

Tuesday, 7 March 2017 at 16:30

Add to Calendar ▼2017-03-07 16:30:002017-03-07 17:30:00Europe/LondonThe Discovery and Development of E209 - a Tetraoxane Based Rapidly Acting

E209 is a superior next generation antimalarial endoperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities of artemisinin derivatives. Here we present the drug discovery programme leading to the development of E209.

Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAcademic Drug